We found that more than two-thirds of (beneficiaries) were assigned to plans that covered every single one of the drugs they were actually taking. Only 8.2% were assigned to plans that covered less than 70% of their drugs.
Our analysis shows there have not been any significant price increases at all and pretty big savings. We have done a much wider monitoring and have not found any large changes in drug prices except where there was a data error.